US · Healthcare · Biotechnology
EPS came in at -0.28 against a street estimate of -0.26 — a miss of 7.7%.
Analysts rate Summit Therapeutics PLC a buy (11 buy, 6 hold, 0 sell out of 17) with an average price target of $30.20.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 4.11% |
| FMR Inc | 1.26% |
| State Street Corp | 1.20% |
| BlackRock Inc | 1.19% |
| Vanguard Capital Management, LLC | 0.72% |
| UBS Group AG | 0.66% |
| Vanguard Portfolio Management, LLC | 0.63% |
| The Goldman Sachs Group Inc | 0.57% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 HEADLINE NUMBERS • Summit Therapeutics agreed to raise $2.0 billion in gross proceeds from AstraZeneca Holdings B.V., an AstraZeneca plc subsidiary. | 2026-09-29 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Summit Therapeutics Inc. (Nasdaq: SMMT) • Headquarters: 601 Brickell Key Dri | 2026-09-15 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Summit Therapeutics Inc. (NASDAQ: SMMT) • Filing Date: September 13, 2026 • | 2026-09-14 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this filing — this is a current report on a clinical | 2026-09-03 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. (SMMT) - 8-K SUMMARY HEADLINE NUMBERS • Filing date: August 26, 2026 • Report covers event dated August 25, 2026 • Company: | 2026-08-26 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. (SMMT) – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Summit Therapeutics announced expansion of its clinical developme | 2026-08-05 |
| Quarterly report · Q2 2026 SUMMIT THERAPEUTICS INC. - Q2 2026 SUMMARY HEADLINE NUMBERS • Cash position: $419.4 million in cash and cash equivalents, $271.3 million in short-te | 2026-07-23 |
| Material agreement · Q3 2026 SUMMIT THERAPEUTICS INC. — 8-K FILING SUMMARY HEADLINE NUMBERS • Company entered into distribution agreement on July 23, 2026 to offer and sell up t | 2026-07-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| Expansion of clinical development program for ivonescimab into urothelial carcinoma Summit Therapeutics announced expansion of its clinical development program for ivonescimab, a cancer drug candidate, into a new indication: bladder cancer (urothelial carcinoma). The compan | 2026-08-05 |
| Clinical trial collaboration with GSK to evaluate ivonescimab combination Summit Therapeutics announced three significant developments on January 12, 2026. First, the company reported preliminary cash and short-term investments of approximately $710 million as of | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Summit Therapeutics PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.